Oncolytics Biotech Secures Patent Protection for Pelareorep into Late 2040s

Oncolytics Biotech® Inc. (Nasdaq: ONCY) announced on Oct. 12, 2026, that it has secured new patent protection for its lead candidate, pelareorep, with the goal of extending intellectual property rights into the late 2040s. The clinical-stage immunotherapy company stated that a new method of use patent covering pelareorep as an immunotherapy for the treatment of cancer has been issued in several countries. The company expects the corresponding U.S. patent to issue in the near term.

Current and Pending Patent Portfolio

The new patent issuances build on Oncolytics’ existing manufacturing patent protection, which runs through 2044. According to the company, the new method of use patents are intended to extend protection for specified therapeutic uses and future innovations into the late 2040s, subject to patent issuance and applicable patent terms.

Oncolytics currently has three patent application families pending. These include multiple method of use patents addressing certain combination therapies, such as pelareorep in connection with immunotherapies and targeted therapies. The company stated that this quarter, it expects to convert one of these pending applications into a U.S. application submitted with a request for Track One prioritized examination. This specific application is directed to the use of pelareorep as a therapy that induces immunologic responses.

The U.S. Patent and Trademark Office’s Track One program provides prioritized examination with a goal of reaching a final disposition within approximately 12 months after prioritized status is granted. Oncolytics noted that while the program can accelerate examination and provide earlier clarity on the scope of potential patent protection, prioritized examination does not guarantee patent allowance.

Next Generation Pelareorep

In parallel with its current patent strategy, Oncolytics is working with an academic partner on a modified form of pelareorep, which the company refers to as “next generation” pelareorep. Oncolytics expects this work to support the addition of a new composition of matter patent to its portfolio. This potential patent would provide a separate layer of protection for the modified pelareorep, with the potential for up to 20 years of patent protection measured from the applicable filing date.

The company stated that the modified pelareorep is being developed with the expectation that it could provide enhanced efficacy. However, Oncolytics emphasized that this potential enhanced efficacy will require confirmation through further studies.

Executive Commentary

Jared Kelly, Chief Executive Officer of Oncolytics, addressed the strategic importance of these intellectual property developments.

“We are expanding our patent portfolio to protect how pelareorep is manufactured, how it is used to treat cancer, and the innovations that could define its next generation,” said Jared Kelly, Chief Executive Officer of Oncolytics. “Our existing manufacturing protection through 2044 provides a strong foundation. The additional method of use patents and potential new composition of matter protection are intended to extend that foundation into the late 2040s and support the long-term development and commercial potential of pelareorep.”

Why it matters

For Oncolytics Biotech, the extension of patent protection is critical for the long-term commercial viability of pelareorep. By securing method of use patents and pursuing composition of matter protection for a modified version of the drug, the company aims to maintain exclusivity for its therapeutic applications beyond the current manufacturing patent expiration in 2044. The success of these efforts depends on the claims ultimately granted by patent offices and the results of further studies confirming the efficacy of the next generation variant.

---

Sources

• financialpost.com: Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update | Financial Post
• stocktitan.net: Oncolytics Biotech targets patent protection into late 2040s | ONCY Stock News

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.